Trending...
- Update Any Sign Instantly with Santek EZ Sign NFC: Ultra-Slim 4-Color E-Paper Display - 824
- Hypnotic Hijinks of HypnoMarc Rolls into Sunnyvale for One Night Only
- THINKWARE Unveils U3000 PRO: Flagship 4K/2K Dash Cam With Dual RADAR and Next-Gen Connected Services
PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
More on The Californer
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
Related Links
http://www.kodiak.com
- Jefferies Virtual Healthcare Conference on Thursday, June 3 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time)
- Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 1:40 p.m. Pacific Time (4:40 p.m. Eastern Time)
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
More on The Californer
- 20/20 Optometry of Silicon Valley Celebrates 25 Years of Vision Care for the Bay Area!
- PDS Plumbing & Air Honors Veterans with "Free Tune-Up & A Turkey" Giveaway
- PowerMy Introduces Independent Solar Diagnostics Platform to Help Homeowners Save Money
- Hiller's 2025 Flight Simulator Rally Inspires Golf Sim Revolution in Access and Training
- AgeImmune Announces the Launch of ImmuneG.I. — A Doctor-Formulated Herbal Supplement Supporting Gut and Digestive Wellness
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
Related Links
http://www.kodiak.com
Filed Under: Business
0 Comments
Latest on The Californer
- Rachel Farris, CPA Featured in High Net Worth Magazine
- Rachel Farris Joins "Money Tree Investing" Podcast to Explore Puerto Rico's Act 60
- $5.4 Million Growth Acceleration, Fleet Expansion and $1.485 Million Strategic Financing: Multi Ways Holdings (N Y S E: MWG) $MWG
- Delta Capital Group Expands Business Funding Terms Up to 24 Months
- 3 New Members Join The Ventura College Foundation Board, Including Acting Ventura College President
- The Paramount Swap Meet's First Annual Día de los Muertos Celebration featuring a Catrina Contest
- Governor Newsom highlights California innovation with Lockheed Martin Skunk Works' X-59 named "Coolest Thing Made in California"
- Health Care Foundation for Ventura County Receives $2 Million Grant to Expand Mammography Services
- Hip-HopVibe.com Launches HHV Media Network in Partnership with The Publisher Desk
- CCHR: Misinformation Clouds Debate on Psychiatric Drug Toxicology Transparency
- Hilton Head Realtor becomes Certified Senior Professional
- ELKLOOK's 2025 Halloween Sale is Officially Launched
- Bitcoin at $115K: AZETHIO Launches Exchange Targeting Institutional Compliance Requirements
- Tech gains propel Dow Jones past 47,000 as markets reach record highs amid trade tensions
- Edu Alliance Group Launches the Center for College Partnerships and Alliances
- Three Cord True Wealth Management Unveils New Website for Better Client Communication
- WrightOne Media Group Expands Experiential & Content Divisions, Appoints Influencer Leslie Mosier Head of Social Media
- Generation Own: Why Young Americans Are Skipping Corporate Careers to Buy Million-Dollar Businesses
- Dongsheng's Titanium Recycling Business Enters Aerospace Sector by 2025
- Crowdfunding Campaign Tips Off for 'NAWFSIDE' Short Film Highlighting Pressure in Youth Sports